HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco.
Being able to recruit high-risk volunteers who are also willing to consider future participation in vaccine trials are critical features of vaccine preparedness studies. We described data from two cohorts of injection- and non-injection drug users in Barcelona, Spain [Red Cross centre] and in San Francisco, USA, [UFO-VAX study] at high risk of HIV/HCV infection to assess behaviour risk exposure and willingness to participate in future preventive HIV vaccine trials. We successfully identified drug-using populations that would be eligible for future HIV vaccine efficacy trials, based on reported levels of risk during screening and high levels of willingness to participate. In both groups, Red Cross and UFO-VAX respectively, HCV infection was highly prevalent at baseline (41% and 34%), HIV baseline seroprevalence was 4.2% and 1.5%, and high levels of willingness were seen (83% and 78%).
AIDS Research Unit, Hospital Clínic/IDIBAPS-HIVACAT, University of Barcelona, Calle Villarroel 170, 08036, Barcelona, Spain.
M Florencia
MF
Etcheverry
Paula J
PJ
Lum
Jennifer L
JL
Evans
Emilia
E
Sanchez
Elisa
E
de Lazzari
Eva
E
Mendez-Arancibia
Ernesto
E
Sierra
José M
JM
Gatell
Kimberly
K
Page
Joan
J
Joseph
D016915:AIDS Vaccines / Q000276:immunology*; D000328:Adult; D002986:Clinical Trials as Topic; D055030:Drug Users; D005260:Female; D006801:Humans; D008297:Male; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data*; D012495:San Francisco; D013030:Spain; D015819:Substance Abuse, Intravenous
D016915:AIDS Vaccines
Am J Epidemiol. 2003 May 15;157(10):915-22
12746244
Epidemiol Infect. 2007 Apr;135(3):433-42
16893486
J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1667-9
15577428
AIDS. 2005 Oct;19 Suppl 3:S20-5
16251819
Aten Primaria. 2000 Sep 30;26(5):314-8
11100601
J Viral Hepat. 2005 Nov;12(6):655-62
16255768
Southeast Asian J Trop Med Public Health. 2002 Dec;33(4):849-51
12757237
Int J Epidemiol. 1996 Feb;25(1):204-9
8666491
AIDS. 1994 Feb;8(2):223-31
8043227
Drug Alcohol Rev. 2008 May;27(3):286-91
18368610
AIDS Rev. 2005 Jul-Sep;7(3):131-8
16302460
AIDS Behav. 2010 Jun;14(3):607-17
19037720
Drug Alcohol Depend. 2006 Apr;82 Suppl 1:S29-33
16769442
Am J Gastroenterol. 2005 Apr;100(4):825-6
15784026
Epidemiol Infect. 2007 May;135(4):592-603
17005071
Annu Rev Immunol. 2002;20:73-99
11861598
Enferm Infecc Microbiol Clin. 2010 Apr;28(4):236-8
19695744
J Med Virol. 1997 Apr;51(4):338-43
9093950
J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):359-64
15980699
J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):451-7
11035616
AIDS. 2003 Apr 11;17(6):887-93
12660536
Hepatology. 2001 Jul;34(1):180-7
11431749
Drug Alcohol Depend. 2007 Jun 15;89(1):1-12
17174481
J Epidemiol Community Health. 2006 Jun;60(6):537-42
16698987
Eur J Epidemiol. 1998 Sep;14(6):555-61
9794122
Lancet Infect Dis. 2005 Sep;5(9):558-67
16122679
J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):422-31
12447014
Int J STD AIDS. 2007 Jan;18(1):23-7
17326858
J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):162-7
10935692